☆ 4.5 Article

Cost-Effectiveness Analysis of Trastuzumab Deruxtecan versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer in the USA

ADVANCES IN THERAPY (2022)

Related references

Note: Only part of the references are listed.

Article Medicine, General & Internal

Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer

J. Cortes et al.

Summary: Among patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane, trastuzumab deruxtecan was associated with a lower risk of disease progression or death compared to trastuzumab emtansine. However, treatment with trastuzumab deruxtecan was associated with interstitial lung disease and pneumonitis.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Review Health Care Sciences & Services

Cost-effectiveness of treatments for HER2-positive metastatic breast cancer and associated metastases: an overview of systematic reviews

Vakaramoko Diaby et al.

Summary: The treatment of HER2-positive breast cancer has greatly improved with the introduction of targeted therapies. However, the high cost of these treatments raises questions about their cost-effectiveness. Evidence from cost-effectiveness studies suggests caution against global comparisons, emphasizing the importance of local decision-making and economic evaluations.

EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2021)

Add to Collection

Article Oncology

Cost-effectiveness Analysis of Ado-trastuzumab Emtansine (T-DM1) for the Adjuvant Treatment of Patients With Residual Invasive HER2+Early Breast Cancer in the United States

Jesse Sussell et al.

Summary: Cost-effectiveness analysis showed that T-DM1 treatment for HER2+ early breast cancer patients is likely to reduce the overall financial burden of cancer and improve patient outcomes compared to trastuzumab.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2021)

Add to Collection

Article Health Care Sciences & Services

Cost-effectiveness of pertuzumab and trastuzumab as a first-line treatment of HER2-positive metastatic breast cancer in China

Hao Wang et al.

Summary: The study evaluated the cost-effectiveness of PTD and TD regimens in the treatment of HER2-positive MBC patients within the Chinese health system. Results showed that while the PTD regimen offered advantages in life extension and quality of life improvement compared to the TD regimen, the increased costs did not meet the current economic threshold in China.

ANNALS OF PALLIATIVE MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer

Shanu Modi et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Oncology

Cost-Effectiveness of Tucatinib in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer From the US and Chinese Perspectives

Qiuji Wu et al.

FRONTIERS IN ONCOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Breast cancer

Nadia Harbeck et al.

NATURE REVIEWS DISEASE PRIMERS (2019)

Add to Collection

Article Oncology

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Freddie Bray et al.

CA-A CANCER JOURNAL FOR CLINICIANS (2018)

Add to Collection

Article Oncology

Cost-effectiveness analysis of 1st through 3rd line sequential targeted therapy in HER2-positive metastatic breast cancer in the United States

Vakaramoko Diaby et al.

BREAST CANCER RESEARCH AND TREATMENT (2016)

Add to Collection

Review Medicine, General & Internal

Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses Second Panel on Cost-Effectiveness in Health and Medicine

Gillian D. Sanders et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)

Add to Collection

Article Oncology

Necitumumab in Metastatic Squamous Cell Lung Cancer Establishing a Value-Based Cost

Daniel A. Goldstein et al.

JAMA ONCOLOGY (2015)

Add to Collection

Editorial Material Medicine, General & Internal

Updating Cost-Effectiveness - The Curious Resilience of the $50,000-per-QALY Threshold

Peter J. Neumann et al.

NEW ENGLAND JOURNAL OF MEDICINE (2014)

Add to Collection

Article Oncology

Weekly paclitaxel plus trastuzumab in metastatic breast cancer pretreated with anthracyclines-a phase II multipractice study

Matthias John et al.

BMC CANCER (2012)

Add to Collection

Article Health Care Sciences & Services

Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves

Patricia Guyot et al.

BMC MEDICAL RESEARCH METHODOLOGY (2012)

Add to Collection

Review Oncology

Treatment of HER2-positive breast cancer: current status and future perspectives

Carlos L. Arteaga et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2012)

Add to Collection

Article Medicine, General & Internal

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

Sunil Verma et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

Add to Collection

Article Oncology

Quality of life among women recently diagnosed with invasive breast cancer: the Pathways Study

Marilyn L. Kwan et al.

BREAST CANCER RESEARCH AND TREATMENT (2010)

Add to Collection

Editorial Material Medicine, General & Internal

Legislating against Use of Cost-Effectiveness Information

Peter J. Neumann et al.

NEW ENGLAND JOURNAL OF MEDICINE (2010)

Add to Collection

Article Economics

An Empiric Estimate of the Value of Life: Updating the Renal Dialysis Cost-Effectiveness Standard

Chris P. Lee et al.

VALUE IN HEALTH (2009)

Add to Collection

© Peeref 2019-2024. All rights reserved.